YY-20394 is primarily investigated for its potential therapeutic applications in the field of oncology. It is being studied as a selective inhibitor of PI3Kδ, a key enzyme involved in the PI3K/AKT/mTOR signaling pathway, which plays a critical role in cell growth, survival, and metabolism. By targeting this pathway, YY-20394 shows promise in treating certain types of cancers, particularly hematologic malignancies like chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Its selective inhibition of PI3Kδ aims to minimize off-target effects, potentially offering a safer and more effective treatment option compared to broader PI3K inhibitors. Preclinical and clinical studies are ongoing to evaluate its efficacy, safety, and potential as a targeted cancer therapy.